Gary J. Schwartz

https://assets.montefioreeinstein.org/profiles/images/9621-gary-schwartz.jpg

First Name

Gary

Last Name

Schwartz

Faculty ID

9621

Patient Type

Adult

Department

Email

Phone

Titles

Locations

Professional Interests

<p>Gary J. Schwartz, Ph.D., studies how the gut and the brain interact with each other to regulate food intake and associated metabolic processes.&nbsp; Dr. Schwartz and his colleagues aim to identify therapeutic targets for eating behaviors associated with obesity, diabetes and related diseases.</p>
<p>Our research focuses on the sensory neural controls of energy homeostasis in health and disease. We use rodent models to examine how food stimuli act at oral and gastrointestinal sites to affect food intake, energy balance, and gastrointestinal physiology.We approach this problem from multiple levels of analysis including behavioral, physiological, neurophysiological, and molecular-genetic. We have identified the type of food stimuli that activate vagal and splanchnic sensory fibers supplying the gut, and have revealed the extent to which these stimuli influence gut-brain communication. Our most recent efforts involve the analysis of gut-brain communication in the control of energy homeostasis in mouse models of obesity and diabetes.We have identified neurons in the periphery, brainstem and hypothalamus that integrate food-elicited signals with peptide signals that have profound effects food intake and metabolism. Data from these studies reveal that central hypothalamic and brainstem neuropeptides affect food intake and body weight by modulating the neural potency of food stimulated signals from the mouth and gut. This novel, synthetic conceptual framework is critical because it links forebrain hypothalamic structures, long known to be involved in the control of energy balance, to the sensory and motor systems in the brainstem that control ingestion, digestion, and metabolic processing of food. Future studies will use genetic mouse models of obesity and diabetes with targeted conditional neuropeptide/ receptor knockdown or replacement to determine how central neuropeptide signaling affects the neural processing of metabolic sensory signals critical to energy homeostasis.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">Dr. Schwartz studies how the gut and the brain act together to determine how much people eat. He has identified sites in the gastrointestinal tract and brain that detect nutrients and has discovered how these regions are linked to food intake, obesity and diabetes. He also studies gastric-bypass surgery and the key neural and hormonal mechanisms responsible for the significant and long-lasting improvements in body weight, food intake and diabetes following the procedure.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">Dr. Schwartz is Director of the Einstein-Mount Sinai Diabetes Research Center Animal Physiology Core at Einstein and Director of the Animal Phenotyping Core of the Columbia University- Einstein New York Obesity Research Center. He also serves on multiple NIH study sections and on scientific grant review panels of the United States Department of Veterans Affairs, American Diabetes Association, Endocrine Fellows Foundation and Obesity Society. He is a member of the editorial boards of several journals, including&nbsp;<em>Diabetes</em>,&nbsp;<em>Endocrinology </em>and serves as an associate editor of the&nbsp;<em>American Journal of Physiology, Endocrinology &amp; Metabolism Section</em>.</span></p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Is Open Scheduling

Off

Jeffrey E. Pessin

https://assets.montefioreeinstein.org/profiles/images/10953-pessin.jpg

First Name

Jeffrey

Last Name

Pessin

Faculty ID

10953

Patient Type

Adult

Department

Email

Phone

Titles

Locations

Professional Interests

<p>The Pessin laboratory is analyzing insulin signaling at the molecular level, the regulation of glucose uptake and metabolism at the cellular, molecular level and the integrative systems of metabolism in normal and pathophysiologic states in genetic rodent models. Our efforts have been focused on three major aspects of insulin signaling and insulin sensitivity. These areas include the molecular mechanisms of adipose tissue inflammation leading to fibrosis and programmed cell death, the regulation of insulin/nutriebt signaling in the regulation of liver gluconeogenesis and lipogenesis and there dysregulation in states of insulin resistance.</p>
<p>One major laboratory project is the investigation of adipocyte progenitor cells, adipocyte programmed cell death and adipose tissue fibrosis that is induced by high fat feeding. In these studies, we have utilized a variety of experimental approaches including genetically engineered mice, Fluorescent Activated Cell Sorting (FACS) analyses and sorting along RNA-Seq and single nuclei RNA-Seq. In these analyses we isolated a variety of inflammatory specific cell types within adipose tissue and have taken extensive use of RNAseq technology to characterize the expression profiles of these various cell subsets. This approach has allowed us to develop a functional understanding of the signaling interplay between the adipose tissue immune cell types to determine the specific role each cell is playing in the inflammatory response. In collaboration with the laboratory of Kosaku Shinoda we are exploring the relationship between metabolism, autophagy and energy balance in adipocyte lineage determination (brown, beige and white) as a potential therapeutic approach for both diabetes and obesity.&nbsp;</p>
<p>A second major laboratory project is based upon our recent findings in collaboration with the laboratory of Fajun Yang that in the fed state CDK8/CycC complex directly phosphorylates the nuclear form of SREBP-1c that induces an E3 ligase mediated ubiquitination and proteasome-mediated degradation of SREBP-1c. This process is one of several that is required to maintain nuclear SREBP1-c at very low levels thereby suppresses lipogenic gene expression and lipogenesis. However, n the fed state, CDK8/CycC proteins are rapidly down regulated through a mTORC1 dependent pathway leading to increased SREBP-1c stability and increased lipogenic gene expression and lipogenesis. During the past two years, we have developed a robust research team, several key mouse genetic models, human liver biopsy speciments and cell based approaches to investigate the regulation of liver gluconeogenesis abd lipogenesis in normal and pathophysiologic states of insulin resistance, obesity and non-alcoholic fatty liver disease (NFALD). In these approaches we perform various high-through put DNA sequencing technologies (ie: RNA-seq, single cell RNA-seq, ChIP-seq, 3 dimensional DNA conformation capture (Hi-C) that are used to directly assess the epigenetic basis of normal and pathological liver metabolic funciton.</p>
<p>We have also initiated new studies to examine the development of heart failure in diabetic cardiomyopathy. New data from the laboratory indicates that increasing glycolytic rate in cardiomyocytes markedly protects the heart from myocardial infarction. In collaboration with the laboratory of Gaetano Santulli, we are examining the mechanistic basis for this novel observation as a means to specifcally prevent heart damage and failure that progressively occurs following myocardial infarction.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">Dr. Pessin directs the Einstein-Mount Sinai Diabetes Research Center, one of only sixteen NIH-funded diabetes centers of its kind in the country. He guides the research of more than 90 scientists investigating type 1 (formerly juvenile) and type 2 (formerly adult-onset) diabetes. The center also includes training programs and community-based activities in the Bronx. Dr. Pessin&rsquo;s own research focuses on insulin signaling and the mechanisms contributing to the onset of type 1 diabetes.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">Dr. Pessin also studies how adult progenitor cells (cells that have the capacity to differentiate into a specific cell type) influence the development of fat tissue and how mechanical signals influence stem cell development. The findings from such research have led to animal models for studying insulin resistance and diabetes.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">Dr. Pessin is associate editor of Diabetes, the peer-reviewed journal of the American Diabetes Association, and the former editor-in-chief of<span>&nbsp;</span><em>Endocrinology</em><span>&nbsp;</span>and the <em>American Journal of Physiology - Endocrinology and Metabolism</em>. He has received the Eli Lilly Outstanding Investigator Award of the American Diabetes Association and the Mary Jane Kugel Award of the Juvenile Diabetes Research Foundation International.</span></p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/33812059/"><span style="color: #0071bc;">The Mediator complex kinase module is necessary for fructose regulation of liver glycogen levels through induction of glucose-6-phosphatase catalytic subunit (G6pc).</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Youn DY, Xiaoli AM, Zong H, Okada J, Liu L, Pessin J,&nbsp;<strong>Pessin JE</strong>, Yang F.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">Mol Metab. 2021 Jun;48:101227. doi: 10.1016/j.molmet.2021.101227. Epub 2021 Mar 31.PMID:&nbsp;33812059&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/33667344/"><span style="color: #0071bc;">Conversion of the death inhibitor ARC to a killer activates pancreatic &beta; cell death in diabetes.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">McKimpson WM, Chen Y, Irving JA, Zheng M, Weinberger J, Tan WLW, Tiang Z, Jagger AM, Chua SC Jr,&nbsp;<strong>Pessin JE</strong>, Foo RS, Lomas DA, Kitsis RN.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">Dev Cell. 2021 Mar 22;56(6):747-760.e6. doi: 10.1016/j.devcel.2021.02.011. Epub 2021 Mar 4.PMID:&nbsp;33667344</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/32848017/"><span style="color: #0071bc;">ATG16L1 autophagy pathway regulates BAX protein levels and programmed cell death.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Chen F, Amgalan D, Kitsis RN,&nbsp;<strong>Pessin JE</strong>, Feng D.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">J Biol Chem. 2020 Oct 30;295(44):15045-15053. doi: 10.1074/jbc.RA120.013999. Epub 2020 Aug 26.PMID:&nbsp;32848017&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/32635651/"><span style="color: #0071bc;">The Impact of Single-Cell Genomics on Adipose Tissue Research.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Deutsch A, Feng D,&nbsp;<strong>Pessin JE</strong>, Shinoda K.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">Int J Mol Sci. 2020 Jul 5;21(13):4773. doi: 10.3390/ijms21134773.PMID:&nbsp;32635651&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/32570757/"><span style="color: #0071bc;">FAM83G Is a Novel Inducer of Apoptosis.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Okada J, Sunaga N, Yamada E, Saito T, Ozawa A, Nakajima Y, Okada K,&nbsp;<strong>Pessin JE</strong>, Okada S, Yamada M.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">Molecules. 2020 Jun 18;25(12):2810. doi: 10.3390/molecules25122810.PMID:&nbsp;32570757&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/32075912/"><span style="color: #0071bc;">Regulation of gene expression during the fasting-feeding cycle of the liver displays mouse strain specificity.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Chi Y, Youn DY, Xiaoli AM, Liu L, Pessin JB, Yang F,&nbsp;<strong>Pessin JE.</strong></span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">J Biol Chem. 2020 Apr 10;295(15):4809-4821. doi: 10.1074/jbc.RA119.012349. Epub 2020 Feb 19.PMID:&nbsp;32075912&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif; vertical-align: top;"><span style="font-family: 'Times New Roman', serif; color: #5b616b;">7</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/32051343/"><span style="color: #0071bc;">SNAP23 depletion enables more SNAP25/calcium channel excitosome formation to increase insulin exocytosis in type 2 diabetes.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Liang T, Qin T, Kang F, Kang Y, Xie L, Zhu D, Dolai S, Greitzer-Antes D, Baker RK, Feng D, Tuduri E, Ostenson CG, Kieffer TJ, Banks K,&nbsp;<strong>Pessin JE</strong>, Gaisano HY.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">JCI Insight. 2020 Feb 13;5(3):e129694. doi: 10.1172/jci.insight.129694.PMID:&nbsp;32051343&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;"><a href="https://pubmed.ncbi.nlm.nih.gov/31979355/"><span style="color: #0071bc;">Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif; color: #212121;">Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y, Ozawa A, Nakajima Y,&nbsp;<strong>Pessin JE</strong>, Okada S, Yamada M.</span><span style="font-family: 'Times New Roman', serif; color: #4d8055;">Molecules. 2020 Jan 23;25(3):495. doi: 10.3390/molecules25030495.PMID: 31979355&nbsp;</span></p>

Is Open Scheduling

Off

Jamie L. Osman-Wager

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/99faf9c0-f4ea-11ed-b165-5b052597da41.jpg

First Name

Jamie

Last Name

Osman-Wager

NPI

1093006652

Faculty ID

14779

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

52406

Biography

<p>Jamie Osman-Wager, MD, MPH, is an attending physician and Assistant Professor, Medicine at Montefiore Einstein. Her clinical focus centers on adult medicine.</p><p>After obtaining her Bachelor of Science from Cornell University in 2005, Dr. Osman-Wager completed a dietetic internship at NewYork-Presbyterian Hospital in 2006. She continued her medical education, earning her Master of Public Health at Harvard in 2010 and her Doctor of Medicine at Montefiore Einstein in 2011. She completed her internal medicine residency at New York University Langone Medical Center in 2014.</p><p>Dr. Osman-Wager&rsquo;s research has been published in numerous peer-reviewed journals and presented at national conferences. She currently serves as site leader at Montefiore Einstein&rsquo;s Moses campus for the third year medical student internal medicine clerkship. Most of her time focuses on educating and training residents and medical students.</p><p>Dr. Osman-Wager is board certified in Internal Medicine and is a member of the American Board of Internal Medicine and the Medical Society of the State of New York. In 2021, she won the Leo M. Davidoff Society Award for Excellence in the Teaching of Medical Students.</p>

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Lisa A. Marrero

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3be5a970-3eab-11ed-a405-bd68d3fd2c32.jpg

First Name

Lisa

Last Name

Marrero

NPI

1164482329

Faculty ID

16492

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>

EMR ID

24681

Visit Type ID

2558

Is Open Scheduling

On

Margaret Levitt

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5ae992a0-3eab-11ed-a405-bd68d3fd2c32.jpg

First Name

Margaret

Last Name

Levitt

NPI

1063472231

Faculty ID

16101

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Pediatric Medicine<quillbot-extension-portal></quillbot-extension-portal>

EMR ID

24270

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Rebecca A. Williams

https://assets.montefioreeinstein.org/profiles/images/10077-rebecca-williams.jpg

First Name

Rebecca

Last Name

Williams

NPI

1841375979

Faculty ID

10077

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Education</strong></p>
<p>Medical School: University of Illinois at Chicago (UIC)<br />Residency: University of Wisconsin, Appleton</p>
<p><strong>Professional Activity</strong></p>
<p>Dr. Rebecca Williams specializes in Family Medicine with concentrated practice in maternity care. She returned to UIC as residency faculty coordinating women&rsquo;s health training. She completed a faculty development fellowship and a master's degree in health professions education. In 2004, she joined the Montefiore Einstein Department of Family and Social Medicine as residency faculty. She currently serves as the Director of Maternity Services for Family Medicine. After years as the sole attending family physician delivering babies at Montefiore hospitals, she now leads a team of family physicians providing care to a large group of women.</p>
<p>Dr. Williams holds an academic appointment in the Department of Family and Social Medicine. She is a member of the Society of Teachers of Family Medicine and teaches residents, students and fellows. She supervises training of residents on labor and delivery and in the office. She directs the Fellowship in Family Centered Maternity Care.</p>
<p>Dr. Williams's research interests are medical education and women&rsquo;s health, with a focus on normal birth.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Family Medicine

Elsevier Profile

Selected Publications

<ol>
<li>Schonberg, D and Williams, RA. Physical Activity in Pregnancy. What Should the Family Physician Recommend? Family Doctor. A Journal of the New York State Academy of Family Physicians. Winter 2013; 2(3):20-2.</li>
<li>NYMC Phelps Family Medicine Residency. AAFP Recommended Curriculum for Family Medicine Residency. Reprint 289C. Practice Based Learning and Improvement. Revised 7/2012.</li>
<li>Williams, RA. Women&rsquo;s Health Content Validity of the Family Medicine In-training Examination. Family Medicine 2007;39:572-7.</li>
<li>Williams RA, Elam G: Gynecology in Rakel RE (Ed.): Textbook of Family Practice, Seventh Edition. Saunders, Philadelphia, 2007.</li>
<li>Williams RA: Breast-feeding in Rakel RE (Ed.): Saunders Manual of Medical Practice, Second Edition. Saunders, Philadelphia, 2000.</li>
<li>Hannon PR, Ehlert-Abler P, Aberman S, Williams RA, Carlos M. Commentary: A Multidisciplinary Approach to Promoting a Baby Friendly Environment in an Urban University Medical Center. Journal of Human Lactation 1999;15:289-296.</li>
</ol>

EMR ID

4657

Biography

<p>Rebecca Williams, MD, MHPE , FAAFP, is Director, Maternity Services and Assistant Professor at Montefiore Einstein. Dr. Williams has more than three decades of experience as a family physician.</p><p>After completing her undergraduate education at the University of Illinois at Urbana-Champaign, Dr. Williams earned her Doctor of Medicine at the University of Illinois at Chicago. She began her postgraduate training in Wisconsin with an internship at Southeastern Family Practice, followed by a residency at Appleton Family Practice.</p><p>Dr. Williams is a Fellow of the American Academy of Family Physicians and a member of the Society of Teachers of Family Medicine.</p>

Is Open Scheduling

On

Kristen Welch

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f668ba00-91b5-11ed-bc46-2f7b4c1ecd09.jpg

First Name

Kristen

Last Name

Welch

NPI

1609220623

Faculty ID

16736

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

122812

Is Open Scheduling

On

Jeffrey M. Weiss

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/56918540-eabd-11ee-964a-bb8efcf16059.jpg

First Name

Jeffrey

Last Name

Weiss

NPI

1841375623

Faculty ID

9980

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jeffrey Weiss, MD is a senior clinician-executive who has taken on progressive leadership positions at Montefiore Health System. Dr. Weiss earned a bachelor of science in industrial and labor relations from Cornell University, a medical degree from Stony Brook School of Medicine, and the Internal Medicine Residency Program at Montefiore, where he was chief resident.</p>
<p>In 2007, Dr. Weiss was named Institutional Medical Director for Montefiore Health System. His role is to help optimize the performance of the Montefiore health delivery network by ensuring a smooth interface between its various components - the doctors, hospital, medical group, home health agency, nursing homes, and the CMO. Dr. Weiss's responsibilities included leadership of nationally recognized patient safety, quality and peer review programs, management of a medical staff with 3,500 employed and voluntary physicians, supervision of GME activities for 1,200 residents in the second largest house staff program in the country, all under the coordinated umbrella of the "Office of the Medical Director" (OMD). As part of a restructuring of organizational clinical leadership in 2012, Dr. Weiss was named Vice President for Medical Affairs. In this role, he has retained many of his previous responsibilities, and is now leading a team of five newly appointed hospital medical directors in driving physician alignment and creating a horizontally integrated approach to quality and clinical performance across the system.</p>
<p>Dr. Weiss is an active clinician, teacher and researcher. He lectures nationally on topics including leadership, physician alignment, and patient safety in several forums, including as a faculty member for the AAMC and National Patient Safety Foundation.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4102

Is Open Scheduling

Off